Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
Type:
Application
Filed:
August 15, 2019
Publication date:
December 5, 2019
Inventors:
Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.
Abstract: The present invention provides stably tagged stem cells and methods for producing stem cells comprising one or more tagged proteins using a gene editing system. The methods described herein enable the insertion of large fluorescent tags into a plurality of genomic loci to generate stem cells that are phenotypically and functional similar to the un-modified parent population. Stem cells produced by the methods described herein additionally retain the capacity to self-renew and differentiate into specialized cell types and can be used in assays and visualization of three-dimensional live cell imaging.
Type:
Application
Filed:
February 9, 2018
Publication date:
December 5, 2019
Inventors:
Ruwanthi GUNAWARDANE, Brock ROBERTS, Amanda HAUPT, Andrew TUCKER
Abstract: A composition for influencing biological growth including live cells, a fluid comprising dextrose, a protectant, and a first cytokine having a first concentration within the composition as described within the present disclosure.
Type:
Application
Filed:
August 19, 2019
Publication date:
December 5, 2019
Inventors:
Christopher D. Jones, Soumyajit Banerjee Mustafi
Abstract: The present invention relates to a complex for promoting cartilage differentiation comprising stem cells or a culture thereof and a cartilage cell-free crush, a method for fabricating cartilage by using the complex, cartilage fabricated via the method, a pharmaceutical composition comprising the complex for preventing or treating arthropathy, a method for preventing or treating arthropathy using the composition, a composition for inducing cartilage cell differentiation comprising the prepared cartilage cells, and a method for fabricating cartilage using the prepared cartilage cells.
Type:
Application
Filed:
July 4, 2017
Publication date:
December 5, 2019
Inventors:
Kyung Sun Kang, Kwang Won Seo, Kyung Ae Yoon, Hyo Jin Jeon, Yun Beom Sim
Abstract: An in vitro method of producing a population of muscle stem cells comprising co-culturing pluripotent stem cells, embryonic fibroblast cells and endothelial cells in 3D cell culture.
Abstract: Disclosed herein are compositions comprising cardiac progenitor cells that express exogenous p53 protein. Such compositions are useful for treating cardiac diseases or disorders. Also disclosed herein are methods of producing cardiac progenitor cells that express exogenous p53.
Abstract: Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed.
Abstract: The present invention relates to the use of eggshell membrane compositions to activate levels of nuclear factor kappa-light-chain-enhancer of activated B cells (“NF-?B”) in the gut of a host in need thereof and methods of treating conditions related to NF-?B dysregulation.
Abstract: Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.
Abstract: An object of the present invention is to provide: a Tau protein production accelerator containing a natural product as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. Provided are: a Tau protein production accelerator containing a dry powder ground product and/or extract of an earthworm as an active ingredient; a therapeutic or preventive agent for a disease caused by Tau protein deficiency; and a therapeutic or preventive food composition for a disease caused by Tau protein deficiency. The disease caused by Tau protein deficiency is preferably Alzheimer's disease.
Abstract: Provided is a composition for treating a diabetic disease, which serves as a meal substitution for a patient having the diabetic disease. The composition contains a vegetable powder mixture and/or cricket powders.
Abstract: The present invention provides a fermented product obtained by fermenting honey and camomile or a treated product thereof with Lactobacillus kunkeei.
Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.
Type:
Application
Filed:
November 17, 2017
Publication date:
December 5, 2019
Inventors:
Yan Li, Scott Peterson, Linda Bradley, Roberto Tinoco, Ze`ev Ronai, Shiri Ashkenazi
Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
Type:
Application
Filed:
August 19, 2019
Publication date:
December 5, 2019
Applicant:
REBIOTIX, INC.
Inventors:
Lee A. Jones, Courtney R. Jones, Beth Anne-Szkudlarek Brown, Joshua Erickson
Abstract: The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a Pediococcus acidilactici probiotic. Compositions of Pediococcus acidilactici probiotic are also provided.
Abstract: The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis. In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.
Type:
Application
Filed:
January 17, 2018
Publication date:
December 5, 2019
Inventors:
Marcus Rudolf GÖTZ, Kerstin HOLMGREN, Niklas LARSSON, Bernd FIEBICH, William WADE
Abstract: The subject matter of the instant invention relates to methods of compounding compositions comprising bacteriophage effective for treating bacterial infections, including but not limited to, multidrug resistant bacterial infections. The invention also relates to compositions, bacterial diversity sets, and phage libraries prepared according to the methods of the instant invention.
Type:
Application
Filed:
June 7, 2019
Publication date:
December 5, 2019
Applicant:
United States of America as Represented by the Secretary of the Navy
Inventors:
James M. Regeimbal, Biswajit Biswas, Matthew S. Henry
Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.
Type:
Application
Filed:
November 3, 2017
Publication date:
December 5, 2019
Applicants:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Christian FIEDLER, Leopold GRILLBERGER, Meinhard HASSLACHER, Barbara KRAUS, Dominik MITTERGRADNEGGER, Stefan REUBERGER, Horst SCHAFHAUSER, Marian BENDIK
Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of UFM1 activity or expression and/or an inhibitor of UFL1 activity or expression to reduce a cancer cell's ability to carry out a DDR, thereby increasing the sensitivity of cancer cells to treatment with a DNA damaging therapy such as radiation or chemotherapy, are provided.
Type:
Application
Filed:
January 11, 2018
Publication date:
December 5, 2019
Applicant:
Mayo Foundation for Medical Education and Research
Inventors:
Evanthia GALANIS, S. Keith ANDERSON, Cheyne B. KUROKAWA, Ianko D. IANKOV
Abstract: This anti-NASH composition, this food composition for preventing NASH, and this beverage composition for preventing NASH include, as an active ingredient, a Basidiomycetes-X FERM BP-10011 dry powder or an extract composition thereof. In addition, a composition for preventing cirrhosis and a composition for preventing hepatocellular carcinoma include, as an active ingredient, a Basidiomycetes-X FERM BP-10011 dry powder or an extract composition thereof, and prevent metastasis of cirrhosis and hepatocellular carcinoma from NASH.
Type:
Application
Filed:
February 6, 2018
Publication date:
December 5, 2019
Inventors:
Kenichi WATANABE, Tetsuya KONISHI, Yusuke KOGA
Abstract: Provided are a method of efficiently producing a ginseng leaf extract including rare ginsenosides Rg6, Rk3, and Rh4 in increased amounts, and use of a ginseng leaf extract produced by the method.
Type:
Application
Filed:
May 31, 2019
Publication date:
December 5, 2019
Applicant:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventors:
Jungyeob HAM, Taejung KIM, Young Tae PARK, Kyusun KIM, Pilju CHOI, Seon-Jun CHOI, Bong Geun SONG, Jae Young CHOI
Abstract: The invention discloses synergistic compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula for improving the liver health. The invention further discloses method of improving the liver health in humans and animals by administering the compositions comprising at least one component selected from extract(s) and fraction(s) or mixtures thereof derived from Sphaeranthus indicus in combination with at least one component selected from extract(s), fraction(s), active compound(s) or mixtures thereof derived from Terminalia chebula.
Abstract: The present invention discloses a cancer treatment method which includes the step of treating a patient having cancer with an extract from Galenia africana L. plant. The extract may include pinocembrin and/or 2?,4? dihydroxychalcone and/or 7-hydroxyflavanone. The cancer may be breast cancer or melanoma. The composition may be solubilized with MPG and/or Suganate.
Abstract: The present disclosure relates to the field of healthcare foods. Disclosed is a composition having functions of improving kidney yang, enhancing immunity and relieving fatigue, which is an aqueous extract of ASTRAGALI RADIX, REHMANNIAE RADIX, EUCOMMIAE CORTEX, MORINDAE OFFICINALIS RADIX, LYCII FRUCTUS and POLYGONATI RHIZOMA. By using six traditional Chinese herb medicines, ASTRAGALI RADIX, REHMANNIAE RADIX, EUCOMMIAE CORTEX, MORINDAE OFFICINALIS RADIX, LYCII FRUCTUS and POLYGONATI RHIZOMA for decoction extraction, a composition having functions of improving kidney yang, enhancing immunity and relieving fatigue is obtained. Through synergetic function of each traditional Chinese herb medicine, the composition achieves a better effect comparing with similar products. In addition, the species of traditional Chinese medicine in the composition is relatively fewer, lowering the potential safety hazard, and the method is simple and the cost is low.
Abstract: Compositions for improving erectile function or treating erectile dysfunction include active ingredients of Muira Puama extract, Quercetin, Chlorophytum Borivilianum (Safed Musli), Dimethylethanolamine (DMAE), niacin, Tribulus Terrestris extract, alpha-lipoic acid, Horny Goat Weed (Epimedium grandfiflorum), Panax ginseng, and saw palmetto berry extract, and may also include magnesium aspartate, Zinc oxide, and Maca root (Lepidium meyenii). Additional active ingredients include Avena Sativa extract (oat straw), L-Taurine, L-Lysine hydrochloride (HCl), a L-Arginine, and/or L-Carnitine.
Type:
Application
Filed:
January 3, 2019
Publication date:
December 5, 2019
Inventors:
Yong Wu, Ke Wu, Gordon Lee, Wei Cao, Huabing Yang
Abstract: Disclosed are the antimicrobial effects of bioactive compounds isolated from Curcuma species and their derivatives. Specifically, the invention discloses the growth inhibition of and management of infections caused by Enteroaggregative Escherichia coli (EAEC), Enterotoxigenic Escherichia coli (ETEC) and Pleisiomonas species by curcuminoids, calebin A and their derivatives.
Type:
Application
Filed:
May 29, 2018
Publication date:
December 5, 2019
Inventors:
Anju Majeed, Muhammed Majeed, Kalyanam Nagabhushanam, Nooruddin Thajuddin, Sivakumar Arumugam, Krishnamurthy Kulithalai Viswanathan, Samuel Thomas Manoharan, Furqan Ali, John Adams Sebastian
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
Type:
Application
Filed:
April 22, 2019
Publication date:
December 5, 2019
Inventors:
Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues car organs.
Abstract: A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
Type:
Application
Filed:
April 9, 2019
Publication date:
December 5, 2019
Inventors:
Paolo Angeli, Penelope Markham, Jonathan Adams
Abstract: Absorbent structures for absorbent articles are provided. The absorbent structure includes an absorbent layer with absorbent material supported by a supporting sheet, and a channel that is free of said absorbent material. The channel has a wet integrity of at least 20%.
Type:
Application
Filed:
August 15, 2019
Publication date:
December 5, 2019
Inventors:
Rodrigo ROSATI, Carsten Heinrich KREUZER, Hans Adolf JACKELS, Blanca ARIZTI, Ernesto G BIANCHI, Donald Carroll ROE
Abstract: The present invention is directed to antimicrobial agents and compositions including the same. The antimicrobial agent can include a polypeptide or a peptidomimetic of the polypeptide. The polypeptide can have a net positive charge of at least about 3 at a pH of 7.0, and a hydrophobicity of greater than 25%.
Abstract: SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.
Abstract: Disclosed herein are recombinant baculoviruses suitable for introducing an exogenous gene into a pest insect, particularly, disease-transmitting mosquitos. The recombinant baculovirus is characterized in having a promotor that is any of a HzNV-1 viral early expressing gene pag1, a ceropin gene b1, a defensin gene a4, or hp70 gene; and an exogenous gene operably linked thereto the promoter. Also disclosed herein is a method of introducing an exogenous gene into a pest insect. The method includes transducing the pest insect with a recombinant baculovirus without suppressing the production of microRNAs (miRNAs) in the pest insect, wherein the recombinant baculovirus comprises a promoter of pag1, cecropin b1, defensin gene a, or hp70.
Type:
Application
Filed:
May 30, 2018
Publication date:
December 5, 2019
Applicants:
Academia Sinica, Chung Yuan Christian University, National Defense Medical Center
Abstract: Provided herein are methods and compositions useful for human health, e.g., for targeting one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the modulation resulting in a decrease in the fitness of the host. The invention features a composition that includes a modulating agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the modulating agent described herein may be used to decrease the fitness of a variety of insects that carry vector-borne pathogens that cause disease in humans.
Type:
Application
Filed:
January 24, 2018
Publication date:
December 5, 2019
Inventors:
Ignacio MARTINEZ, Zachary Garo ARMEN, Christine CEZAR, Barry Andrew MARTIN, Maier Steve AVENDANO AMADO
Abstract: Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention
Abstract: A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
Abstract: The present invention is based on the seminal concept of treating pain by promoting neuronal differentiation. The invention provides a screening method for the selection of agents for the purpose of treating pain, utilizing neuronal differentiation as selection criteria. Methods and libraries available for screening for the selection of candidate agents are provided.
Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.
Abstract: The disclosure relates to methods and compositions for rejuvenating neuromuscular junctions, and treating, preventing, or delaying the onset of, neuromuscular junction fragmentation and related disorders, neuromuscular junction degeneration and related disorders, motor neuron degeneration and related disorders, skeletal muscle conditions (e.g., muscle atrophy), and neuromuscular diseases (e.g., amyotrophic lateral sclerosis).
Abstract: The present invention provides a preventive or therapeutic agent for an inflammatory skin disease, such as psoriasis, the agent comprising an oligopeptide as an active ingredient. More specifically, the invention provides a preventive or therapeutic agent for an inflammatory skin disease, the agent comprising an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a ?-strand D sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.
Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.
Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
Type:
Application
Filed:
April 18, 2019
Publication date:
December 5, 2019
Inventors:
Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
Abstract: Compositions that specifically cleave target sequences in Flavivirus, for example Zika virus include a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) associated endonuclease, a guide RNA sequence complementary to a target sequence in a Zika virus and an anti-viral agent. These compositions are administered to a subject for treating an infection or at risk for contracting a Zika virus infection.
Type:
Application
Filed:
October 12, 2017
Publication date:
December 5, 2019
Inventors:
Kamel Khalili, Ilker K. Sariyer, Hassen Wollebo
Abstract: This document relates to methods and materials for treating functional dyspepsia. For example, methods and materials for using secretin to treat functional dyspepsia are provided.
Type:
Application
Filed:
December 20, 2017
Publication date:
December 5, 2019
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
Type:
Application
Filed:
August 19, 2019
Publication date:
December 5, 2019
Inventors:
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS